CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate

Journal of Virology

Volumn 78, Issue 22, 2004, Pages 12288-12296

  Zerhouni, Bouchra ^a   Nelson, Julie A E ^b   Saha, Kunal ^a,c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR4;

ARTICLE; CELLULAR IMMUNITY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; GENOTYPE; HIV-1; HUMANS; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS REPLICATION;

EID: 7644224182     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.22.12288-12296.2004     Document Type: Article

References (39)

1. Aarons, E. J., S. Beddows, T. Willingham, L. Wu, and R. A. Koup. 2001. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287:382-390.
2. Agosto, M., J. Allan, C. Benson, E. A. Berger, R. Blumenthal, D. Burton, J. Clements, J. Coffin, R. Connor, B. Cullen, R. Desrosiers, D. Dimitrov, R. Doms, M. Emerman, M. Feinberg, P. Fultz, C. Gerard, G. Gonsalves, A. Haase, N. Haigwood, V. Hirsch, D. Ho, J. A. Hoxie, S. L. Hu, D. Zingale, et al. 1998. AIDS vaccine development. Science 280:803-805.
3. + cells. J. Virol. 78:2277-2287.
4. Armand-Ugon, M., M. E. Quinones-Mateu, A. Gutierez, J. Barretina, J. Blanco, D. Schols, E. De Clercq, B. Clotet, and J. A. Este. 2003. Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir. Ther. 8:1-8.
5. Baribaud, F., T. G. Edwards, M. Sharron, A. Brelot, N. Bereiter, K. Price, F. Mortari, M. Alizon, M. Tsang, and R. W. Doms. 2001. Antigenically distinct conformations of CXCR4. J. Virol. 75:8957-8967.
6. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
7. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930.
8. Burgisser, P., P. Vernazza, M. Flepp, J. Boni, Z. Tomasik, U. Hummel, G. Pantaleo, and J. Schupbach. 2000. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 23:138-144.
9. Burton, D. R., R. C. Desrosiers, R. W. Doms, M. B. Feinberg, R. C. Gallo, B. Hahn, J. A. Hoxie, E. Hunter, B. Korber, A. Landay, M. M. Lederman, J. Lieberman, J. M. McCune, J. P. Moore, N. Nathanson, L. Picker, D. Richman, C. Rinaldo, M. Stevenson, D. I. Watkins, S. M. Wolinksky, and J. A. Zack. 2004. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 303:316.
10. Chenine, A. L., M. Pion, E. Matouskova, F. Gondois-Rey, R. Vigne, and I. Hirsch. 2002. Adaptation of a CXCR4-using human immunodeficiency type 1 NDK virus in intestinal cells is associated with CD4-independent replication. Virology 304:403-414.
11. De Clercq, E. 2000. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol. 57:833-839.
12. De Clercq, E. 2002. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta 1587:258-275.
13. Doms, R. W. 2001. Chemokine receptors and HIV entry. AIDS 15(Suppl. 1):S34-S35.
14. Este, J. A. 2001. TAK-779 (Takeda). Curr. Opin. Investig. Drugs 2:354-356.
15. Este, J. A., C. Cabrera, J. Blanco, A. Gutierrez, G. Bridger, G. Henson, B. Clotet, D. Schols, and E. De Clercq. 1999. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73: 5577-5585.
16. Fauci, A. S. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534.
17. Glushakova, S., Y. Yi, J. C. Grivel, A. Singh, D. Schols, E. De Clercq, R. G. Collman, and L. Margolis. 1999. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J. Clin. Investig. 104:R7-R11.
18. Hendrix, C. W., C. Flexner, R. T. MacFarland, C. Giandomenico, E. J. Fuchs, E. Redpath, G. Bridger, and G. W. Henson. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:1667-1673.
19. + lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J. Virol. 72:9054-9060.
20. Kitrinos, K. M., N. G. Hoffman, J. A. Nelson, and R. Swanstrom. 2003. Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J. Virol. 77:6811-6822.
21. Labrosse, B., A. Brelot, N. Heveker, N. Sol, D. Schols, E. De Clercq, and M. Alizon. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:6381-6388.
22. Labrosse, B., J. L. Labernardiere, E. Dam, V. Trouplin, K. Skrabal, F. Clavel, and F. Mammano. 2003. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. 77:1610-1613.
23. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20:73-99.
24. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
25. + T lymphocytes. Blood 96:1853-1856.
26. McMichael, A. J., and R. E. Phillips. 1997. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15:271-296.
27. Nelson, J. A., S. A. Fiscus, and R. Swanstrom. 1997. Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J. Virol. 71:8750-8758.
28. Owen, S. M., D. Rudolph, D. Schols, N. Fujii, N. Yamamoto, and R. B. Lal. 2002. Susceptibility of diverse primary HIV isolates with varying co-receptor specificities to CXCR4 antagonistic compounds. J. Med. Virol. 68:147-155.
29. Reeves, J. D., S. Hibbitts, G. Simmons, A. McKnight, J. M. Azevedo-Pereira, J. Moniz-Pereira, and P. R. Clapham. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J. Virol. 73:7795-7804.
30. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J. Virol. 72:876-881.
31. Saha, K., M. Caruso, and D. J. Volsky. 1997. Human immunodeficiency virus type 1 (HIV-1) infection of herpesvirus saimiri-immortalized human CD4-positive T lymphoblastoid cells: evidence of enhanced HIV-1 replication and cytopathic effects caused by endogenous interferon-gamma. Virology 231: 1-9.
32. Saha, K., and D. J. Volsky. 1998. Are beta-chemokines innocent bystanders in HIV type 1 disease progression? AIDS Res. Hum. Retrovir. 14:1-2. (Letter.)
33. + T lymphocytes using CD8 as a receptor. Nat. Med. 7:65-72.
34. + T cells in patients with AIDS: implications for HIV-1 pathogenesis. J. Acquir. Immune Defic. Syndr. 26:199-207.
35. Spearman, P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr. HIV Res. 1:101-120.
36. Stalmeijer, E. H., R. P. Van Rij, B. Boeser-Nunnink, J. A. Visser, M. A. Naarding, D. Schols, and H. Schuitemaker. 2004. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J. Virol. 78:2722-2728.
37. + lymphocytes. J. Virol. 78:1243-1255.
38. Zhang, Y., B. Lou, R. B. Lal, A. Gettie, P. A. Marx, and J. P. Moore. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
39. Zhang, Y. J., and J. P. Moore. 1999. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J. Virol. 73:3443-3448.